When Alameda-based biotech company and CIRM awardee Scribe Therapeutics raised over $155 million from a recent IPO, from a recent IPO, it became the latest in a series of companies developing CIRM-supported therapies that have gone public or netted significant follow-on funding and investment. That’s good news for Californians whose tax dollars support the companies’ work. While … Continue reading Another proof point from CIRM-supported research